Loading...

Bruce Cree, MD, PhD

Title(s)Professor, Neurology
SchoolSchool of Medicine
Phone415-353-2069
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.1997 Medicine
    University of California, San FranciscoPh.D.1995 Graduate Division (Biochemistry)
    University of California, San FranciscoM.A.S.2004Clinical Research
    Collapse Awards and Honors
    National Multiple Sclerosis Society, Northern California Chapter 2006Community Service Award
    UCSF, Department of Neurology2009Robert B. Layzer Award for Resident Teaching
    UCSF, School of Medicine2018George A. Zimmermann Endowed Professor in Multiple Sclerosis

    Collapse Overview 
    Collapse Overview
    Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis in the Department of Neurology at the University of California San Francisco. Dr. Cree completed his MD and PhD in Biochemistry at UCSF. His neurology residency training was at Columbia University. He returned to UCSF for a Sylvia Lawry National Multiple Sclerosis Society fellowship and received a Masters in Advanced Studies in Clinical Research. He is the Clinical Research Director at the UCSF MS Center. He divides his time between patient care, clinical research and teaching. His research focuses on the genetic epidemiology of multiple sclerosis, understanding factors that contribute to disease progression and developing novel therapies for MS through clinical trials. In addition to multiple sclerosis, Dr. Cree specializes in research and care of patients with neuromyelitis optica and transverse myelitis.

    Collapse Research 
    Collapse Research Activities and Funding
    Correlating Multiple Sclerosis Phenotypes with Genotypes
    NIH K23NS048869Aug 19, 2005 - Nov 30, 2010
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Ann Neurol. 2018 Jul; 84(1):51-63. PMID: 29908077.
      View in: PubMed
    2. Cree BAC. Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach? J Neuroophthalmol. 2018 Jun; 38(2):258-262. PMID: 29750736.
      View in: PubMed
    3. Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, Schofield L, Tenenbaum N. Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Ther Adv Neurol Disord. 2018; 11:1756286418774338. PMID: 29844796.
      View in: PubMed
    4. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24; 90(17):789-800. PMID: 29686117.
      View in: PubMed
    5. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Apr 24; 90(17):777-788. PMID: 29686116.
      View in: PubMed
    6. Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018 May 15; 90(20):e1815-e1821. PMID: 29669908.
      View in: PubMed
    7. Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 06; 22(7):862-72. PMID: 26666258.
      View in: PubMed
    8. Cree BA. Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult Scler Relat Disord. 2015 Nov; 4(6):536-45. PMID: 26590660.
      View in: PubMed
    9. Cree BA. Genetics of primary progressive multiple sclerosis. Handb Clin Neurol. 2014; 122:211-30. PMID: 24507520.
      View in: PubMed
    10. Cree BA. Acute inflammatory myelopathies. Handb Clin Neurol. 2014; 122:613-67. PMID: 24507538.
      View in: PubMed
    11. Cree BA. Multiple sclerosis genetics. Handb Clin Neurol. 2014; 122:193-209. PMID: 24507519.
      View in: PubMed
    12. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013 Jun; 19(7):835-43. PMID: 23319073.
      View in: PubMed
    13. Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011 Apr; 68(4):464-8. PMID: 21482925.
      View in: PubMed
    14. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50. PMID: 20695007.
      View in: PubMed
    15. Cree BA, Rioux JD, McCauley JL, Gourraud PA, Goyette P, McElroy J, De Jager P, Santaniello A, Vyse TJ, Gregersen PK, Mirel D, Hafler DA, Haines JL, Pericak-Vance MA, Compston A, Sawcer SJ, Oksenberg JR, Hauser SL. A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One. 2010 Jun 25; 5(6):e11296. PMID: 20593013.
      View in: PubMed
    16. Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T, Bar-Or A, Tong C, Hauser SL, Oksenberg JR. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol. 2009 Feb; 66(2):226-33. PMID: 19204159; PMCID: PMC4334456.
      View in: PubMed, PubMed Central
    17. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep. 2008 Sep; 8(5):427-33. PMID: 18713580.
      View in: PubMed
    18. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg JR. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006 Sep 15; 15(18):2813-24. PMID: 16905561.
      View in: PubMed
    19. Cree BC, Bernardini GL, Hays AP, Lowe G. A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol. 2003 Jan; 60(1):107-12. PMID: 12533096.
      View in: PubMed
    20. Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002 Sep; 8(5):290-301. PMID: 12803676.
      View in: PubMed
    Bruce's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (94) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (8) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑